Capricor Therapeutics (NASDAQ:CAPR) shares dropped after the U.S. FDA inspected its San Diego manufacturing facility for the ...

Shares of Capricor Therapeutics (CAPR) were in the spotlight on Wednesday morning after the company announced the completion ...

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in ...

Capricor Therapeutics (CAPR) announced the completion of the Food and Drug Administration’s pre-license inspection of its San ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) announced today that it intends to file a Biologics License Application [BLA] for deramiocel for the treatment of patients with Duchenne Muscular ...

Capricor Therapeutics announced that it has successfully completed the U.S. FDA's Pre-License Inspection of its San Diego manufacturing facility for its lead therapy candidate, Deramiocel ...

The HOPE-2 OLE study continues to show a favorable safety profile for long-term treatment of deramiocel. These data will be shared at this year’s Parent Project Muscular Dystrophy (PPMD ...

U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support ...

We continue to work closely with FDA with the goal of bringing deramiocel to patients as quickly as possible and look forward to sharing further updates as they become available. We thank the ...

With the FDA Advisory Committee meeting now scheduled, we look forward to the opportunity to present the totality of evidence supporting the approval of Deramiocel for the treatment of Duchenne ...

study with its lead asset, deramiocel (CAP-1002), for the treatment of Duchenne muscular dystrophy (DMD).